BRAF and neoplasm: Tumours should be reflexively tested for MMR deficiency, with MMR deficient tumours further tested for MLH1 promoter methylation and/or BRAF c.1799T>A (p.V600E) to exclude sporadic MMR deficient CRCs from the screening pathway.